Skip to content

A prospective controlled study of combined traditional Chinese and western medicine in the treatment of refractory heart failure based on a remote consultation platform

A prospective controlled study of combined traditional Chinese and western medicine in the treatment of refractory heart failure based on a remote consultation platform

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055263
Enrollment
Unknown
Registered
2022-01-05
Start date
2022-01-06
Completion date
Unknown
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Heart Failure

Interventions

Experimental group:Combined treatment of traditional Chinese and western medicine

Sponsors

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for refractory heart failure; 2. Aged >= 18 years; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. The first diagnosis of acute heart failure; 2. Patients with one of the following diseases: (1) acute myocardial infarction; (2) cardiogenic shock; (3) malignant arrhythmia; (4) pulmonary embolism; (5) stroke within the past 6 months; 3. Combined with serious primary diseases such as liver, kidney and hematopoietic system; 4. Mental or intellectual abnormalities, and it is difficult to obtain accurate information on the disease; 5. Those who are pregnant or planning to become pregnant, lactating patients; 6. Suspicious or clear allergy to the test drug; 7. Participate in other researchers within the past 2 months.

Design outcomes

Primary

MeasureTime frame
European Five-Dimensional Health Scale;TCM symptom score;

Secondary

MeasureTime frame
NT-proBNP;Ejection fraction;The ratio of the blood flow velocity of the mitral valve orifice in the early diastole to the velocity of the mitral valve annulus in the early diastole;Left ventricular end-diastolic diameter;Days of hospitalization;

Countries

China

Contacts

Public ContactMao Jingyuan

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

jymao@126.com+86 13820498886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026